| Structure |
Catalog |
Product Name |
CAS |
E3 Ligase |
Target |
Inquiry |
 |
BPL-201453 |
CPD-053 |
2353496-46-3 |
CRBN |
TRKA
TRKB
TRKC |
Inquiry |
|
Molecular Weight: 887.95
Molecular Formula: C47H47F2N9O7
Density: 1.459±0.06 g/cm3
Description: It is a PROTAC that targets TRK for the treatment of cancer.
|
 |
BPL-201454 |
CPD-141 |
2412056-89-2 |
CRBN |
TRKA
TRKB
TRKC |
Inquiry |
|
Molecular Weight: 1050.13
Molecular Formula: C54H61F2N9O11
Density: 1.401±0.06 g/cm3
Description: It is a PROTAC that targets TRK for the treatment of cancer.
|
 |
BPL-201455 |
CPD-145 |
2412056-79-0 |
CRBN |
TRKA
TRKB
TRKC |
Inquiry |
|
Molecular Weight: 799.87
Molecular Formula: C42H42FN11O5
Density: 1.53±0.1 g/cm3
Description: It is a PROTAC that targets TRK for the treatment of cancer.
|
 |
BPL-201456 |
CPD-181 |
2412057-44-2 |
CRBN |
TRKA
TRKB
TRKC |
Inquiry |
|
Molecular Weight: 742.82
Molecular Formula: C40H39FN10O4
Density: 1.52±0.1 g/cm3
Description: It is a PROTAC that targets TRK for the treatment of cancer.
|
 |
BPL-201457 |
CPD-085 |
2412056-56-3 |
CRBN |
TRKA
TRKB
TRKC |
Inquiry |
|
Molecular Weight: 843.92
Molecular Formula: C44H46FN11O6
Density: 1.50±0.1 g/cm3
Description: It is a PROTAC that targets TRK for the treatment of cancer.
|
 |
BPL-201458 |
CPD-143 |
2412056-84-7 |
CRBN |
TRKA
TRKB
TRKC |
Inquiry |
|
Molecular Weight: 843.92
Molecular Formula: C44H46FN11O6
Density: 1.50±0.1 g/cm3
Description: It is a PROTAC that targets TRK for the treatment of cancer.
|
 |
BPL-201459 |
CPD-159 |
2412056-64-3 |
CRBN |
TRKA
TRKB
TRKC |
Inquiry |
|
Molecular Weight: 798.88
Molecular Formula: C43H43FN10O5
Density: 1.49±0.1 g/cm3
Description: It is a PROTAC that targets TRK for the treatment of cancer.
|
 |
BPL-201460 |
CPD-211 |
2412058-12-7 |
CRBN |
TRKA
TRKB
TRKC |
Inquiry |
|
Molecular Weight: 782.84
Molecular Formula: C42H39FN10O5
Density: 1.58±0.1 g/cm3
Description: It is a PROTAC that targets TRK for the treatment of cancer.
|
![(4R)-N-[2-[3-[[5-[4-[3-[6-Cyano-5-(trifluoromethyl)-3-pyridinyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]phenoxy]pentyl]oxy]propoxy]acetyl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-L-prolinamide](https://resource.bocsci.com/structure/1973402-26-4.gif) |
BPL-201461 |
(4R)-N-[2-[3-[[5-[4-[3-[6-Cyano-5-(trifluoromethyl)-3-pyridinyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]phenoxy]pentyl]oxy]propoxy]acetyl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-L-prolinamide |
1973402-26-4 |
VHL |
AR |
Inquiry |
|
Molecular Weight: 1021.19
Molecular Formula: C50H59F3N8O8S2
Density: 1.38±0.1 g/cm3
Description: It is a PROTAC that targets androgen receptor used in cancer Therapeutics (prostate cancer and Kennedy's diseases).
|
![(4R)-N-[2-[3-[[5-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluorophenoxy]pentyl]oxy]propoxy]acetyl]-3-methyl-L-valyl-4-hydroxy-N-[(1S)-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]-L-prolinamide](https://resource.bocsci.com/structure/1973402-35-5.gif) |
BPL-201462 |
(4R)-N-[2-[3-[[5-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluorophenoxy]pentyl]oxy]propoxy]acetyl]-3-methyl-L-valyl-4-hydroxy-N-[(1S)-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]-L-prolinamide |
1973402-35-5 |
VHL |
AR |
Inquiry |
|
Molecular Weight: 1052.23
Molecular Formula: C52H61F4N7O8S2
Density: 1.37±0.1 g/cm3
Description: It is a PROTAC that targets androgen receptor used in cancer Therapeutics (prostate cancer and Kennedy's diseases).
|
![(4R)-N-[2-[3-[[5-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2,6-difluorophenoxy]pentyl]oxy]propoxy]acetyl]-3-methyl-L-valyl-4-hydroxy-N-[(1S)-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]-L-prolinamide](https://resource.bocsci.com/structure/1973402-36-6.gif) |
BPL-201463 |
(4R)-N-[2-[3-[[5-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2,6-difluorophenoxy]pentyl]oxy]propoxy]acetyl]-3-methyl-L-valyl-4-hydroxy-N-[(1S)-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]-L-prolinamide |
1973402-36-6 |
VHL |
AR |
Inquiry |
|
Molecular Weight: 1070.22
Molecular Formula: C52H60F5N7O8S2
Density: 1.38±0.1 g/cm3
Description: It is a PROTAC that targets androgen receptor used in cancer Therapeutics (prostate cancer and Kennedy's diseases).
|
![(4R)-N-[2-[3-[4-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluorophenoxy]butoxy]propoxy]acetyl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-L-prolinamide](https://resource.bocsci.com/structure/1973402-52-6.gif) |
BPL-201464 |
(4R)-N-[2-[3-[4-[4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluorophenoxy]butoxy]propoxy]acetyl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-L-prolinamide |
1973402-52-6 |
VHL |
AR |
Inquiry |
|
Molecular Weight: 1024.17
Molecular Formula: C50H57F4N7O8S2
Density: 1.39±0.1 g/cm3
Description: It is a PROTAC that targets androgen receptor used in cancer Therapeutics (prostate cancer and Kennedy's diseases).
|
![(4R)-N-[2-[3-[4-[4-[3-[6-Cyano-5-(trifluoromethyl)-3-pyridinyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]phenoxy]butoxy]propoxy]acetyl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-L-prolinamide](https://resource.bocsci.com/structure/1973402-55-9.gif) |
BPL-201465 |
(4R)-N-[2-[3-[4-[4-[3-[6-Cyano-5-(trifluoromethyl)-3-pyridinyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]phenoxy]butoxy]propoxy]acetyl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-L-prolinamide |
1973402-55-9 |
VHL |
AR |
Inquiry |
|
Molecular Weight: 1007.17
Molecular Formula: C49H57F3N8O8S2
Density: 1.39±0.1 g/cm3
Description: It is a PROTAC that targets androgen receptor used in cancer Therapeutics (prostate cancer and Kennedy's diseases).
|
![(4R)-N-[2-[3-[4-[4-[3-(3-Chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]phenoxy]butoxy]propoxy]acetyl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-L-prolinamide](https://resource.bocsci.com/structure/1973402-56-0.gif) |
BPL-201466 |
(4R)-N-[2-[3-[4-[4-[3-(3-Chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]phenoxy]butoxy]propoxy]acetyl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-L-prolinamide |
1973402-56-0 |
VHL |
AR |
Inquiry |
|
Molecular Weight: 972.63
Molecular Formula: C49H58ClN7O8S2
Density: 1.37±0.1 g/cm3
Description: It is a PROTAC that targets androgen receptor used in cancer Therapeutics (prostate cancer and Kennedy's diseases).
|
![(2S,4R)-1-((S)-2-(2-(3-(4-((4'-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-[1,1'-biphenyl]-4-yl)oxy)butoxy)propoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide](https://resource.bocsci.com/structure/protac1590.gif) |
BPL-201467 |
(2S,4R)-1-((S)-2-(2-(3-(4-((4'-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-[1,1'-biphenyl]-4-yl)oxy)butoxy)propoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
|
VHL |
AR |
Inquiry |
|
Molecular Weight: 1082.28
Molecular Formula: C56H62F3N7O8S2
Description: It is a PROTAC that targets androgen receptor used in cancer Therapeutics (prostate cancer and Kennedy's diseases).
|
 |
BPL-201468 |
XH1 |
2370866-38-7 |
RNF114 |
BRD4 |
Inquiry |
|
Molecular Weight: 1143.76
Molecular Formula: C61H67ClN6O12S
Density: 1.43±0.1 g/cm3
Description: Nimbolide impairs breast cancer cell proliferation in part by disrupting RNF114-substrate recognition, leading to inhibition of ubiquitination and degradation of tumor suppressors such as p21, resulting in their rapid stabilization.
|
 |
BPL-201469 |
XH2 |
2365403-47-8 |
RNF114 |
BRD4 |
Inquiry |
|
Molecular Weight: 1025.62
Molecular Formula: C56H57ClN6O9S
Density: 1.47±0.1 g/cm3
Description: Nimbolide impairs breast cancer cell proliferation in part by disrupting RNF114-substrate recognition, leading to inhibition of ubiquitination and degradation of tumor suppressors such as p21, resulting in their rapid stabilization.
|
![4-(3,4-Dimethyl-7-oxo-2-(p-tolyl)-2,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)butanamide](https://resource.bocsci.com/structure/2428629-30-3.gif) |
BPL-201470 |
4-(3,4-Dimethyl-7-oxo-2-(p-tolyl)-2,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)butanamide |
2428629-30-3 |
CRBN |
PDEdelta |
Inquiry |
|
Molecular Weight: 652.71
Molecular Formula: C34H36N8O6
Density: 1.46±0.1 g/cm3
Description: It is a PDEδ degrader for the treatment of KRAS mutant colorectal cancer.
|
![4-(3,4-Dimethyl-7-oxo-2-(p-tolyl)-2,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)butanamide](https://resource.bocsci.com/structure/2428629-31-4.gif) |
BPL-201471 |
4-(3,4-Dimethyl-7-oxo-2-(p-tolyl)-2,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)butanamide |
2428629-31-4 |
CRBN |
PDEdelta |
Inquiry |
|
Molecular Weight: 666.74
Molecular Formula: C35H38N8O6
Density: 1.44±0.1 g/cm3
Description: It is a PDEδ degrader for the treatment of KRAS mutant colorectal cancer.
|
![4-(3,4-Dimethyl-7-oxo-2-(p-tolyl)-2,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentyl)butanamide](https://resource.bocsci.com/structure/2428629-32-5.gif) |
BPL-201472 |
4-(3,4-Dimethyl-7-oxo-2-(p-tolyl)-2,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentyl)butanamide |
2428629-32-5 |
CRBN |
PDEdelta |
Inquiry |
|
Molecular Weight: 680.77
Molecular Formula: C36H40N8O6
Density: 1.42±0.1 g/cm3
Description: It is a PDEδ degrader for the treatment of KRAS mutant colorectal cancer.
|
